Key result
Sitagliptin significantly improved endothelial function compared to conventional treatment, demonstrated by a greater percent change in the reactive hyperemia peripheral arterial tonometry index (62.4% vs. 15.9%, P<0.01).
Why the study?
Does sitagliptin improve endothelial function in patients with coronary artery disease and uncontrolled diabetes?
Does sitagliptin improve endothelial function in patients with coronary artery disease and uncontrolled diabetes?
Absolute Event Rate: 62.4% vs 15.9%
p-value: p=<0.01
Sitagliptin improves endothelial function and reduces inflammation in patients with CAD and uncontrolled diabetes, independent of its glucose-lowering effects.
No takes yet. Share an insight, caveat, or question.
Sitagliptin-associated endothelial improvement in small CAD-DM cohort warrants outcome trials; should not yet change practice.
Matsubara et al. (2013) studied Coronary artery disease and uncontrolled type-2 diabetes mellitus (n=40). Sitagliptin vs. Aggressive conventional treatment was evaluated on Percent change in reactive hyperemia peripheral arterial tonometry index (RHI) (p=<0.01). Sitagliptin significantly improved endothelial function compared to conventional treatment, demonstrated by a greater percent change in the reactive hyperemia peripheral arterial tonometry index (62.4% vs. 15.9%, P<0.01).